Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Jun;10(Suppl 17):S1986-S1988.
doi: 10.21037/jtd.2018.04.156.

Can molecularly targeted therapy cure patients with resected EGFR mutant NSCLC?

Myron Klevansky  1 , Thomas John  1   2
Affiliations
Editorial

Can molecularly targeted therapy cure patients with resected EGFR mutant NSCLC?

Myron Klevansky et al. J Thorac Dis. 2018 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: A/Prof. Tom John: Consulting: BMS, Merck, Takeda, AstraZeneca, Boehringer Ingelheim, Novartis; Honoraria: BMS, Merck, AstraZeneca, Novartis. M Klevansky has no conflicts of interest to declare.

Comment in

Comment on

References

    1. Goss GD, O’Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR 19 Study. J Clin Oncol 2013;31:3320-26. 10.1200/JCO.2013.51.1816 - DOI - PMC - PubMed
    1. Kelly K, Altorki N, Wilfred E, et al. Adjuvant erlotinib versus placebo in patients with state IB-IIIA non-small-cell lung cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2015;33:4007-14. 10.1200/JCO.2015.61.8918 - DOI - PubMed
    1. Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol 2018;19:139-48. 10.1016/S1470-2045(17)30729-5 - DOI - PubMed
    1. Arriagada R, Auperin A, Burdett S, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375:1267-7. - PMC - PubMed
    1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9. 10.1200/JCO.2007.13.9030 - DOI - PubMed